ZANTAC 300
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 300 is an oral capsule H2-receptor antagonist approved in 1994 for the treatment of gastric acid-related disorders. The mechanism of action involves blocking histamine H2 receptors to reduce gastric acid secretion. This is a mature, well-established therapeutic agent in the gastrointestinal disease space.
LOE Approaching
LOE-approaching lifecycle signals potential team restructuring; commercial roles may shift to defend market share against generics and newer competitors with moderate competitive pressure (30%).
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal declining investment in ZANTAC 300; career opportunities are limited and primarily defensive in nature. Professionals joining this product should expect stable but non-growth roles focused on market maintenance and generic competition management.
Brand ManagerField Sales Representative
Worked on ZANTAC 300 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.